Down Syndrome Prenatal Screening and Diagnosis: Tests, Timing, and Decision-Making
Multiple options exist to assess fetal risk for trisomy 21 (Down syndrome). Choice depends on gestational age, risk tolerance, and values.
Screening Tests (Risk Estimation)
First Trimester (11–13+6 weeks)
- Combined test: Nuchal translucency (NT) ultrasound + maternal serum PAPP-A, free β-hCG. Detection ~85–90%, FPR 5%.
- Cell-free DNA (NIPT): Fetal fraction from maternal blood; >99% detection, <0.1% FPR for T21. Also screens T18, T13, sex chromosomes.
Second Trimester (15–22 weeks)
- Quad screen: AFP, hCG, estriol, inhibin-A. Detection ~81%, FPR 5%.
- Integrated/sequential: Combines 1st + 2nd trimester markers.
Diagnostic Tests (Definitive)
- CVS (10–13 weeks): Chorionic villus sampling; karyotype/CMA. Miscarriage risk ~0.2–0.5%.
- Amniocentesis (15–20+ weeks): Amniotic fluid karyotype/CMA. Risk ~0.1–0.3%.
Decision Framework
- Screening → if high risk → diagnostic confirm.
- NIPT increasingly used as primary screen (cost/access permitting).
- Diagnostic offered directly if: age ≥35, prior affected pregnancy, ultrasound anomalies, parental translocation.
Counseling Essentials
- Non-directive; explore values, preparation, termination vs. continuation resources.
- Support organizations (NDSC, DSE, local groups).
Informed choice requires understanding test limitations (screening ≠ diagnosis) and personal priorities.
Pregnancy & Health - Related Articles
- Spotting in Early Pregnancy: When to Be Concerned
- Your Fertile Window: When Conception Is Most Likely
- Coughing During Pregnancy: Can It Cause Miscarriage?
- When Does a Pregnant Belly Start to Show?
- Medication Risks in Early Pregnancy: Teratogens and Miscarriage Risk
- Fetal Movement: When You'll Feel Kicks and What to Watch For
- Light Brown Discharge Before Period: Implantation, Ovulation, or Other Causes
